2022
DOI: 10.7759/cureus.21863
|View full text |Cite
|
Sign up to set email alerts
|

Rhabdomyosarcoma With Diffuse Bone Marrow Metastases

Abstract: Rhabdomyosarcoma is a highly aggressive cancer that is generally considered a disease of childhood. A vast majority of cases occur in those below the age of 20. Rhabdomyosarcoma can occur in any soft tissue in the body but is primarily found in the head, neck, orbit, genitourinary tract, genitals, and extremities. Prognosis is closely tied to the location of the primary tumor and the extent of metastatic spread. As with most sarcomas, rhabdomyosarcoma has a pattern of hematogenous spread which favors metastasi… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
3
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
4

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(3 citation statements)
references
References 20 publications
0
3
0
Order By: Relevance
“…However, radiographic findings of RMS are largely nonspecific. 18 F‐FDG PET/CT has been reported to be of great value in RMS staging and risk stratification, and is also used to detect unknown primary sites or sites of rare metastases, treatment decisions, prognostic prediction, and treatment response evaluation [ 7 , 8 ].…”
Section: Discussionmentioning
confidence: 99%
“…However, radiographic findings of RMS are largely nonspecific. 18 F‐FDG PET/CT has been reported to be of great value in RMS staging and risk stratification, and is also used to detect unknown primary sites or sites of rare metastases, treatment decisions, prognostic prediction, and treatment response evaluation [ 7 , 8 ].…”
Section: Discussionmentioning
confidence: 99%
“…Rhabdomyosarcoma (RMS) is the most common pediatric soft-tissue sarcoma with an incidence of 0.4 cases per 100,000 children per year in the United States [ 1 ]. Patients with metastatic disease, alveolar histology, or the presence of an oncogenic FOXO1 fusion have a poorer prognosis [ 2 , 3 ]. Rare cases of RMS with extensive bone marrow involvement without a definitive primary site have been reported [ 3 ].…”
Section: Introductionmentioning
confidence: 99%
“…Patients with metastatic disease, alveolar histology, or the presence of an oncogenic FOXO1 fusion have a poorer prognosis [ 2 , 3 ]. Rare cases of RMS with extensive bone marrow involvement without a definitive primary site have been reported [ 3 ].…”
Section: Introductionmentioning
confidence: 99%